Aptose Biosciences appoints Ernst & Young auditor

Executive Summary

• Aptose Biosciences held a reconvened annual and special shareholders meeting on August 22, 2025, where shareholders approved the appointment of Ernst & Young LLP (EY) as the company's new independent registered public accounting firm.
• Concurrently, the company announced the receipt of an additional $1.5 million (U.S.) advance from Hanmi Pharmaceutical Co. Ltd., bringing the total amount drawn under the existing $8.5 million loan facility to $7.1 million (U.S.).
• The financing proceeds are designated to support the continued clinical development of the company's lead drug candidate, tuspetinib.

Key Details

• Shareholder Vote Results: Shareholders voted in favor of appointing Ernst & Young LLP as the new independent auditor, replacing previous auditors.
• New Auditor Details: EY was selected based on their global expertise, capabilities, and specific understanding of the life sciences sector.
• Financing Advance: Aptose received an additional $1.5 million (U.S.) advance from Hanmi Pharmaceutical Co. Ltd.
• Total Drawdown: The aggregate amount received under the loan facility announced on June 20, 2025, is now $7.1 million (U.S.).
• Facility Terms: The total facility size is $8.5 million (U.S.).
• Use of Proceeds: Funds are intended to support the continued clinical development of tuspetinib.
• Product Context: Tuspetinib is a clinical-stage, oral kinase inhibitor being developed for relapsed/refractory acute myeloid leukemia (AML) and as a frontline triplet therapy in newly diagnosed AML.

Notable Quotes

• "We are pleased to welcome Ernst & Young as our new auditor," said Fletcher Payne, senior vice-president and chief financial officer and chief business officer of Aptose. "Their global expertise and deep experience in the life sciences sector will support our continued growth and commitment to transparency."